PMC:7228307 / 43883-44007 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"796","span":{"begin":60,"end":67},"obj":"Gene"}],"attributes":[{"id":"A796","pred":"tao:has_database_id","subj":"796","obj":"Gene:2214"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T369","span":{"begin":81,"end":103},"obj":"Body_part"}],"attributes":[{"id":"A369","pred":"fma_id","subj":"T369","obj":"http://purl.org/sig/ont/fma/fma55675"}],"text":"Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T25","span":{"begin":81,"end":103},"obj":"Body_part"},{"id":"T26","span":{"begin":89,"end":103},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"uberon_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0001016"}],"text":"Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T777","span":{"begin":14,"end":18},"obj":"http://purl.obolibrary.org/obo/CLO_0053432"},{"id":"T778","span":{"begin":60,"end":62},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T779","span":{"begin":81,"end":103},"obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"T780","span":{"begin":81,"end":103},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T781","span":{"begin":81,"end":103},"obj":"http://www.ebi.ac.uk/efo/EFO_0000908"}],"text":"Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"796","span":{"begin":60,"end":67},"obj":"Gene"}],"attributes":[{"id":"A796","pred":"pubann:denotes","subj":"796","obj":"Gene:2214"}],"text":"Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T250","span":{"begin":0,"end":124},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T25","span":{"begin":81,"end":103},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"uberon_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"}],"text":"Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T485","span":{"begin":14,"end":18},"obj":"Protein"}],"attributes":[{"id":"A485","pred":"uniprot_id","subj":"T485","obj":"https://www.uniprot.org/uniprot/Q9BRD6"},{"id":"A486","pred":"uniprot_id","subj":"T485","obj":"https://www.uniprot.org/uniprot/Q96S68"},{"id":"A487","pred":"uniprot_id","subj":"T485","obj":"https://www.uniprot.org/uniprot/Q542B2"},{"id":"A488","pred":"uniprot_id","subj":"T485","obj":"https://www.uniprot.org/uniprot/Q3LRP3"},{"id":"A489","pred":"uniprot_id","subj":"T485","obj":"https://www.uniprot.org/uniprot/P25918"},{"id":"A490","pred":"uniprot_id","subj":"T485","obj":"https://www.uniprot.org/uniprot/P25917"},{"id":"A491","pred":"uniprot_id","subj":"T485","obj":"https://www.uniprot.org/uniprot/P15391"},{"id":"A492","pred":"uniprot_id","subj":"T485","obj":"https://www.uniprot.org/uniprot/F5H635"},{"id":"A493","pred":"uniprot_id","subj":"T485","obj":"https://www.uniprot.org/uniprot/A0N0P9"}],"text":"Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T368","span":{"begin":81,"end":103},"obj":"Body_part"}],"attributes":[{"id":"A368","pred":"fma_id","subj":"T368","obj":"http://purl.org/sig/ont/fma/fma55675"}],"text":"Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}

{"project":"LitCovid-sample-PD-MAT","denotations":[{"id":"T17","span":{"begin":81,"end":103},"obj":"http://purl.obolibrary.org/obo/MAT_0000457"},{"id":"T18","span":{"begin":89,"end":103},"obj":"http://purl.obolibrary.org/obo/MAT_0000026"}],"text":"Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T20","span":{"begin":105,"end":113},"obj":"Phenotype"}],"attributes":[{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}

{"project":"LitCovid-sentences","denotations":[{"id":"T250","span":{"begin":0,"end":124},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T20","span":{"begin":105,"end":113},"obj":"Phenotype"}],"attributes":[{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III"}